

Ref: FOI/GS/ID 6761

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

11 June 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the incidence and treatment of breast cancer.

You asked:

1. *How many patients have you treated (using surgery, radiotherapy or any systemic anti-cancer therapy) in the last three months for:*
 - a. *Breast cancer (any stage)*
 - b. *Early breast cancer (both early-stage and locally advanced, inclusive of stages I-IIIc)*
 - c. *Metastatic breast cancer (stage IV)*
2. *How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:*
 - a. *Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
 - b. *Abemaciclib + Fulvestrant*
 - c. *Anthracycline (e.g. doxorubicin or epirubicin) as a single agent*
 - d. *Atezolizumab + Nab-paclitaxel/Paclitaxel*
 - e. *Capecitabine as a single agent*
 - f. *Carboplatin or Cisplatin as a single agent*
 - g. *Eribulin as a single agent or in combination*
 - h. *Everolimus + Exemestane*
 - i. *Fluorouracil*
 - j. *Fulvestrant as a single agent*
 - k. *Lapatinib*
 - l. *Neratinib*
 - m. *Olaparib*
 - n. *Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
 - o. *Palbociclib + Fulvestrant*
 - p. *Pertuzumab + Trastuzumab + Docetaxel*

- q. *Platinum (e.g. carboplatin or cisplatin) as a single agent*
- r. *Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- s. *Ribociclib + Fulvestrant*
- t. *Talazoparib*
- u. *Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- v. *Transtuzumab as a single agent or in combination*
- w. *Trastuzumab emtansine*
- x. *Any other active systemic anti-cancer therapy*

Trust response:

- 1. Unable to answer this question.
- 2. These figures relate to the period 1/3/2021-31/5/202:
 - a. 0
 - b. 4
 - c. 0
 - d. 1
 - e. 11
 - f. 1
 - g. 1
 - h. 3
 - i. 0
 - j. 0
 - k. 0
 - l. 0
 - m. 0
 - n. 68
 - o. 21
 - p. 7
 - q. See f) above
 - r. 5
 - s. 0
 - t. 0
 - u. 9
 - v. 72 NB includes those in p) above
 - w. 9
 - x. 44